Diagnosis and treatment of benign prostatic hyperplasia: Practice patterns of primary care physicians

Journal of General Internal Medicine

Volumn 12, Issue 4, 1997, Pages 224-229

  Collins, Mary McNaughton ^a   Barry, Michael J ^a   Bin, Lin ^b   Roberts, Richard G ^c   Oesterling, Joseph E ^d   Fowler, Floyd J ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

practice guideline; practice patterns; primary care physicians; prostatic hyperplasia

Indexed keywords

FINASTERIDE;

ADULT; ARTICLE; FEMALE; HEALTH CARE POLICY; HUMAN; MALE; MEDICAL PRACTICE; NORMAL HUMAN; PRIMARY MEDICAL CARE; PROSTATE HYPERTROPHY;

ADULT; AGED; FAMILY PRACTICE; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; POPULATION SURVEILLANCE; PRACTICE GUIDELINES; PRIMARY HEALTH CARE; PROSTATIC HYPERPLASIA; RANDOM ALLOCATION; REFERRAL AND CONSULTATION; SAMPLING STUDIES; UROLOGY;

EID: 0030975453     PISSN: 08848734     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1497.1997.012004224.x     Document Type: Article

References (27)

1. Barry MJ, Boyle P, Fourcroy J, et al. Epidemiology and natural history of BPH. In: Cockett ATK, Khoury S, Aso Y, et al. The 3rd International Consultation on BPH: Proceedings. Paris, France: Scientific Communication International: 1996:21-50.
2. Monda JM, Oesterling JE. Medical treatment of benign prostatic hyperplasia: 5-alpha-reductase inhibitors and alpha-adrenergic antagonists. Mayo Clin Proc. 1993;68:670-9.
3. McConnell JD, Barry MJ, Bruskewitz RC, et al. Benign prostatic hyperplasia: Diagnosis and Treatment. Clinical Practice Guideline, No 8, Rockville, Md: Agency for Health Care Policy and Research, Public Health Service, United States Department of Health and Human Services; 1994. AHCPR. Publication No. 94-0582.
4. Barry MJ, Fowler FJ, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992;148:1549-57.
5. O'Leary MP, Barry MJ, Fowler FJ. Hard measures of subjective outcomes: validating symptom indexes in urology. J Urol 1992;148: 1546-8.
6. Barry MJ, Fowler FJ, Bin L, Oesterling JE. A nationwide survey of practicing urologists: current management of benign prostatic hyperplasia and clinically localized prostate cancer. J Urol. In press.
7. Rosner B. Fundamentals of Biostatistics. Boston. Mass: PWS Kent; 1990.
8. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 1996;335:533-9.
9. Plawker MW, Fleisher JM, Nitti VW, Macchia RJ. Primary care practitioners: an analysis of their perceptions of voiding dysfunction and prostate cancer. J Urol. 1996;155:601-4.
10. Partin AW. Prostate cancer-educating ourselves and our nonurological colleagues. J Urol. 1996;155:610-11. Editorial.
11. Meigs JB, Barry MJ, Oesterling JE, Jacobsen SJ. Does prostate-specific antigen testing make less sense for men with prostatic hyperplasia than for unselected men? J Gen Intern Med. 1996;11: 505-12.
12. Barry MJ, Fleming C, Coley CM, Wasson JH, Fahs MC, Oesterling JE. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part I: framing the debate. Urology. 1995;46:2-13.
13. Catalona WJ, Richie JP, Ahman FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283-90.
14. Walsh PC. Using prostate-specific antigen to diagnose prostate cancer: sailing in uncharted waters. Ann Intern Med. 1993;119: 948-9.
15. Middleton RG, Thompson IM, Austenfeld MS, et al. Prostate cancer clinical guidelines panel summary report on the management of clinically localized prostate cancer. J Urol. 1995;154:2144-8.
16. Stress JK, Harlan WR. The dissemination of new medical information. JAMA. 1979;241:2622-4.
17. Jacobsen SJ, Girman CJ, Guess HA, et al. New diagnostic and treatment guidelines for benign prostatic hyperplasia: potential impact in the United States. Arch Intern Med. 1995;155:477-81.
18. Roberts RG. BPH: new guidelines based on symptoms and patient preference. Geriatrics. 1994;49:24-31.
19. Oesterling JE. Benign prostatic hyperplasia: medical and minimally invasive treatment options. N Engl J Med. 1995;332:99-109.
20. McNaughton Collins MF, Friedman RH, Ash A, Hall R, Moskowitz MA. Underdetection of clinical benign prostatic hyperplasia in a general medicine practice. J Gen Intern Med. 1996;11:513-8.
21. Kassirer JP. Access to specialty care. N Engl J Med. 1994;331: 1151-3. Editorial.
22. Greenfield S. Dividing up the turf: generalists versus subspecialists. J Gen Intern Med. 1996;11:245-6. Editorial.
23. Neilson KG. When does a generalist need a specialist? J Gen Intern Med. 1996;11:247-8. Editorial.
24. Eddy DM. Clinical decision making: from theory to practice: three battles to watch in the 1990's. JAMA. 1993;270:520-6.
25. Lee TH. Beyond guidelines: can general internists show the (critical) paths? J Gen Intern Med. 1996;11:174-5.
26. Hayward RSA, Wilson MC, Tunis SR, Guyatt GH, Moore KA, Bass EB. Practice guidelines: what are internists looking for? J Gen Intern Med. 1996;11:176-8.
27. Greco PJ, Eisenberg JM. Changing physicians' practices. N Engl J Med. 1993;329:1271-4.